Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles

Background: The healthy microbiome protects against the development of Clostridium difficile infection (CDI), which typically develops following antibiotics. The microbiome metabolises primary to secondary bile acids, a process if disrupted by antibiotics, may be critical for the initiation of CDI....

Full description

Bibliographic Details
Main Authors: Allegretti, J. R. (Author), Li, N. (Author), Bogart, E. (Author), Bullock, K. (Author), Gerber, G. K. (Author), Bry, L. (Author), Clish, C. B. (Author), Korzenik, J. R. (Author), Kearney, Sean M (Contributor), Alm, Eric J (Contributor)
Other Authors: Massachusetts Institute of Technology. Department of Biological Engineering (Contributor)
Format: Article
Language:English
Published: Wiley Blackwell, 2017-06-14T20:05:30Z.
Subjects:
Online Access:Get fulltext
LEADER 02855 am a22003013u 4500
001 109870
042 |a dc 
100 1 0 |a Allegretti, J. R.  |e author 
100 1 0 |a Massachusetts Institute of Technology. Department of Biological Engineering  |e contributor 
100 1 0 |a Kearney, Sean M  |e contributor 
100 1 0 |a Alm, Eric J  |e contributor 
700 1 0 |a Li, N.  |e author 
700 1 0 |a Bogart, E.  |e author 
700 1 0 |a Bullock, K.  |e author 
700 1 0 |a Gerber, G. K.  |e author 
700 1 0 |a Bry, L.  |e author 
700 1 0 |a Clish, C. B.  |e author 
700 1 0 |a Korzenik, J. R.  |e author 
700 1 0 |a Kearney, Sean M  |e author 
700 1 0 |a Alm, Eric J  |e author 
245 0 0 |a Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles 
260 |b Wiley Blackwell,   |c 2017-06-14T20:05:30Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/109870 
520 |a Background: The healthy microbiome protects against the development of Clostridium difficile infection (CDI), which typically develops following antibiotics. The microbiome metabolises primary to secondary bile acids, a process if disrupted by antibiotics, may be critical for the initiation of CDI. Aim: To assess the levels of primary and secondary bile acids associated with CDI and associated microbial changes. Methods: Stool and serum were collected from patients with (i) first CDI (fCDI), (ii) recurrent CDI (rCDI) and (iii) healthy controls. 16S rRNA sequencing and bile salt metabolomics were performed. Random forest regression models were constructed to predict disease status. PICRUSt analyses were used to test for associations between predicted bacterial bile salt hydrolase (BSH) gene abundances and bile acid levels. Results: Sixty patients (20 fCDI, 19 rCDI and 21 controls) were enrolled. Secondary bile acids in stool were significantly elevated in controls compared to rCDI and fCDI (P < 0.0001 and P = 0.0007 respectively). Primary bile acids in stool were significantly elevated in rCDI compared to controls (P < 0.0001) and in rCDI compared to fCDI (P = 0.02). Using random forest regression, we distinguished rCDI and fCDI patients 84.2% of the time using bile acid ratios. Stool deoxycholate to glycoursodeoxycholate ratio was the single best predictor. PICRUSt analyses found significant differences in predicted abundances of bacterial BSH genes in stool samples across the groups. Conclusions: Primary and secondary bile acid composition in stool was different in those with rCDI, fCDI and controls. The ratio of stool deoxycholate to glycoursodeoxycholate was the single best predictor of disease state and may be a potential biomarker for recurrence. 
520 |a American College of Gastroenterology (Clinical Research Award ACGJR-017-2015) 
546 |a en_US 
655 7 |a Article 
773 |t Alimentary Pharmacology & Therapeutics